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Abstract
Background: The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small
cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression in ES-SCLC
patients likely to undergo thoracic radiotherapy combined chemotherapy.
Methods: A retrospective review of ES-SCLC patients who had received systemic chemotherapy at our hospital
was performed. Tumor size, metastatic sites, and laboratory data at diagnosis were evaluated as potential prognostic
factors. In ES-SCLC patients without pleural dissemination, the rate of thoracic progression after initial chemotherapy
was assessed.
Results: Eighty-three of 96 consecutive ES-SCLC patients were analyzed. The overall response rate was 55 %, median
progression free survival was 5.0 months (mo), and overall survival (OS) was 9.2 mo. Tumor size (19.4 mo for ≤3 cm vs.
8.5 mo for >3 cm, p = 0.017) and the number of metastatic sites (12.9 mo for single sites vs. 7.1 mo for multiple sites,
p = 0.015) were prognostic factors, in addition to known prognostic factors such as performance status and
the levels of LDH and sodium. Cox proportional hazard model showed that the OS was significantly worse in
patients with large (>3 cm) primary tumor size {HR 2.44 [95 % confidential interval (CI) 1.05–5.68], p = 0.038}
and multiple metastatic sites [HR 1.81 (95 % CI 1.08–3.04), p = 0.026]. In 51 cases without pleural dissemination, the
number of metastatic sites was associated with thoracic progression after initial chemotherapy (65 % for single sites vs.
36 % for multiple sites, p = 0.036).
Conclusion: Large tumor size and multiple metastatic sites at diagnosis significantly predicted poor survival in ES-SCLC
patients. Based on the high rate of thoracic progression in ES-SCLC patients with single site of distant metastasis, we
should consider thoracic radiotherapy combined with chemotherapy for this population.
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Background
Small cell lung cancer (SCLC) is an aggressive disease
characterized by a high propensity for metastases and
a poor prognosis [1, 2]. SCLC is clinically categorized
according to the disease extent as “limited-stage (LS)”
defined as disease that can be encompassed within a
tolerable radiation field and “extensive-stage (ES)” de-
fined as outside of these confines [3]. In LS-SCLC
patients, the addition of early concurrent thoracic
radiotherapy (TRT) to chemotherapy has improved
long-term survival [3–5]. Furthermore, prophylactic
cranial irradiation (PCI) following complete or near-
complete response after induction chemoradiotherapy
provided additional survival benefit [3, 6].
ES-SCLC is a metastatic disease [1]. The standard
treatment against ES-SCLC is combination chemotherapy,
generally platinum plus etoposide or irinotecan [7–9]. Re-
gardless of high sensitivity for initial chemotherapy, the
survival of ES-SCLC patients has improved little in recent
decades, showing 8–13 months (mo) of median survival
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time (MST) with less than 5 % surviving for two years
[1, 10–12]. Recently, combined-modality therapy was
evaluated in ES-SCLC patients. In a European study,
PCI reduced the risk of brain metastases and prolonged
the overall survival (OS) of ES-SCLC patients [13].
However, in a second trial that was conducted in Japan,
the efficacy of PCI in ES-SCLC patients was controver-
sial and the trial was stopped prematurely for futility
[14]. Next, the use of TRT in addition to PCI following
systemic chemotherapy was evaluated because intra-
thoracic progression was common in the European trial
for ES-SCLC patients and 75 % of the patients had
persisting intra-thoracic disease after chemotherapy.
This study suggested that ES-SCLC patients who re-
spond to chemotherapy should be considered for
TRT added to PCI with survival benefit; however, OS
at 1 year, which was the primary endpoint in the
study by Slotman, was not significantly improved (HR
0.84; 95 % CI: 0.69–1.01; p = 0.066) [15]. We surmised that
the results indicated heterogeneity in the ES-SCLC pa-
tients and some of these patients might benefit from TRT.
To further improve the therapeutic efficacy, we hypoth-
esized that TRT combined with chemotherapy should be
considered for selected ES-SCLC patients. We identified
the potential prognostic factors in ES-SCLC patients in
addition to the well-established factors of age, gender, PS,
serum LDH levels, and sodium levels [1]; we retrospect-
ively evaluated ES-SCLC patients treated with systemic
chemotherapy for identifying appropriate patients likely
undergo TRT combined chemotherapy.
Methods
Study patients and clinical data collection
We retrospectively analyzed consecutive ES-SCLC pa-
tients with who had been pathologically diagnosed
with SCLC and began first-line systemic chemother-
apy between July 2008 and December 2012 at the
Kitasato University hospital (Kanagawa, Japan). ES-
SCLC was defined as a disease with distant metasta-
ses over one radiation field. ES-SCLC patients who
had no laboratory and radiologic data before treat-
ment and had a history of prior or concurrent other
malignancy were excluded. The maximum tumor size
of primary lesions using CT imaging, the sites (or-
gans) of metastatic lesions, laboratory data, including
level of Alb, ALP, LDH, sodium, CEA, NSE, and pro-
GRP before treatment were evaluated as candidates of
prognostic factors. After the pretreatment evaluation,
including blood tests, chest X-rays, chest and abdom-
inal CT scans, cranial CT scans or MRIs, and PET or
bone scintigrams, chemotherapy was initiated for ES-
SCLC. The patients’ responses were typically assessed
after 2–4 cycles of systemic chemotherapy, and the
patients returned for follow-up visits at our hospital
each month. If recurrence was suspected, additional
examinations such as CTs and MRIs were performed
in accordance with their doctor’s instructions. OS was
defined as the time from the start of first-line chemother-
apy until death (data cut-off: September 30, 2014). The
retrospective study was approved by the Kitasato Univer-
sity Medical Ethics Organization (B15-78), which waived
the requirement for patients’ informed consent.
Patient characteristics
We identified a total of 96 ES-SCLC patients who were
initially treated with systemic chemotherapy between
January 2009 and December 2012. We excluded four pa-
tients with double cancers and nine patients who were
not evaluated by CT imaging before first-line chemo-
therapy. The analyzed characteristics of the 83 patients
are listed in Table 1. The median size of the primary
tumor was 5.4 cm (range 1.2–10.8 cm). Thirty-two of
the 83 patients (39 %) had pleural dissemination at diag-
nosis and 3 (4 %) had brain metastases. In 36 patients
(43 %), the ES-SCLC had spread to a distant organ, and
in the remaining 47 patients (57 %), it had metastasized
to multiple sites (range 2–5 sites), excluding the hilar,
mediastinal, and subclavicular lymph nodes.
Statistical analyses
All survival analyses were performed using the Kaplan–
Meier method. The survival between the subgroups
based on prognostic factors was compared using a log-
rank test. Multivariate analysis was performed using a
Cox proportional hazard model. The impact of the prog-
nostic factors for the risk of thoracic progression was
assessed using Pearson κ2 test. All analyses were per-
formed using the SPSS statistical package (SPSS Inc,
Chicago, IL).
Results
Effects of chemotherapy
Thirty-three patients (40 %) were treated with platinum-
based combination chemotherapy and 41 patients (49 %)
were given amrubicin monotherapy. Sixty-two patients
(74 %) received three or more cycles of first-line chemo-
therapy, and 54 patients (65 %) received second-line or
more chemotherapy after relapse. The overall response
rate was 55 % (55/83) and the median progression free
survival (PFS) was 5.0 mo (95 % CI: 4.5–5.5 mo).
Twenty-three patients (28 %) relapsed after three mo
from the completion of the initial therapy (sensitive
relapse). The OS was 9.2 mo (95 % CI: 7.6–10.2 mo)
in total cohort: 19.4 mo (95 % CI: 12.9–25.9 mo) for
the sensitive group and 6.9 mo (95 % CI: 6.3–7.6 mo)
for the refractory group (Table 2).
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Evaluation of candidate prognostic factors
Each prognostic factor was assessed using the Kaplan–
Meier method (Additional file 1: Table S1). Performance
status (PS), primary tumor size based on the TNM clas-
sification for lung cancer [16], the number of metastatic
sites, and values such as Alb, LDH, sodium and the
levels of NSE were significantly associated with the sur-
vival in this study. OS was significantly shorter in pa-
tients with large tumors (MST: 8.5 mo for >3 cm vs.
19.4 mo for ≤3 cm, p < 0.02; Fig. 1(1-1)) and those with
multiple metastatic sites (MST: 7.1 mo for multiple sites
vs. 12.9 mo for single sites, p = 0.015; Fig. 1(1-2)). PFS
was also significantly shorter in patients with large
tumors (4.6 mo for >3 cm vs. 6.7 mo for ≤3 cm, p =
0.043; Fig. 1(1-1)), whereas the patients with multiple
metastatic sites had a shorter PFS than those with
single metastatic sites (4.6 mo vs. 5.2 mo, p = 0.065;
Fig. 1(1-2)). The interaction of tumor size and num-
ber of metastatic sites was also significant after ad-
justments for age, gender, PS, LDH levels, and
sodium levels using the multiple Cox proportional
hazard model analysis (large tumor size: HR 2.44,
95 % CI: 1.05–5.68, p = 0.038; multiple metastatic
sites: HR 1.81, 95 % CI: 1.08–3.04, p = 0.026)
(Table 3).
Intra-thoracic progression after initial chemotherapy
The 51 ES-SCLC patients without pleural dissemination
were assessed as a targeted subgroup of ES-SCLC
Table 2 Effects of First-line Chemotherapy for Patients with
ES-SCLC
ES-SCLC (n = 83) %
Regimen
CDDP + CPT 5 6
CDDP + VP-16 3 4
CBDCA + VP-16 20 24
AMRa 41 49
AMR + CPTa 9 11
CDDP + VP-16/AMR + CPTa 5 6
Cycles
1/2 11/10 13/12
3/4 12/36 14/43
5/6 2/12 2/14
Response
Complete response 1 1
Partial response 45 54
Stable disease 10 12
Progression disease 10 12
Not evaluable 17 20
Progressionb
Sensitive relapse 23 28
Refractory relapse 60 72
Survival, median, monthsc
PFS 5.0 (4.5–5.5) -
OS 9.2 (7.6–10.8) -
[OS for sensitive relapse] [19.4 (12.9–25.9)] -
[OS for refractory relapse] [6.9 (6.3–7.6)] -
Note: ES-SCLC extensive-stage small cell lung cancer, CDDP cisplatin, CBDCA
carboplatin, CPT irinotecan, VP-16 etoposide, AMR amrubicin, PFS progression
free survival, OS overall survival
aIncluding patients in clinical trials
bSensitive relapse: Relapsed three months after completion of the initial
therapy, Refractory relapse: Experienced disease progression within
three months
c(): 95 % confidence interval
Table 1 Patient characteristics in this study
ES-SCLC (n = 83) %
Age, median (range), years 71 (47–91)
<75 years 60 72
≥75 years 23 28
Gender
Male/Female 73/10 88/12
Smoking status
Never 2 2
Former/Current 49/30 59/36
Unknown 2 2
WHO performance status
0/1 11/48 13/58
2/3/4 13/9/2 16/11/2
Size of primary tumor, median (range), cm 54 (12–108)
≤3 cm 10 12
>3 cm 73 88
Extensive disease
Intrathoracic disease 23 28
Distant (extrathoracic) metastases 29 35
Both 31 37
Sites of metastases
Brain 3 4
Lung 28 34
Liver 29 35
Adrenal grand 11 13
Bone 25 30
Pleural dissemination 32 39
Othersa 25 30
Number of metastatic sites (organs)
Single (1) 36 43
Multiple (2/3/4/5) 23/17/5/2 28/20/6/2
aIncluding, 10 abdominal and 4 cervical lymph nodes, 4 pancreas, 4 bone
marrow, 3 soft tissue, 1 pericardia, 1 parotid, and 1 ovary metastases
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patients for TRT combined initial chemotherapy. In
these patients, a high rate of thoracic progression
after initial chemotherapy was observed in patients
with single distant metastasis at diagnosis compared
with those with multiple distant metastases (65 % for
single sites vs. 36 % for multiple sites, p = 0.036), in
contrast to primary tumor size (50 % for ≤3 cm vs.
51 % for >3 cm, p = 0.95) (Fig. 2, Additional file 2:
Table S2).
Discussion
The prognosis in ES-SCLC patients is poor; the MST
without treatment has been reported to range from 2
to 4 mo. Chemotherapy remains the cornerstone of
ES-SCLC therapy, although no cure has emerged. Most
approaches, including new chemotherapeutic drugs, mo-
lecular targeted drugs, or maintenance chemotherapy
have not shown improvements successfully [1], and the
MST has improved little in recent decades. Local radio-
therapy, such as PCI and TRT, indicated that the strat-
egy of combined modality therapy was one of the
options for disease control of all stage SCLC.
In European studies, treatment using local radiother-
apy, PCI [13] and TRT in addition to PCI [15], suggested
an improvement in the survival of ES-SCLC patients. In
the first PCI trial, the incidence of symptomatic brain
metastases decreased significantly in the PCI group
compared with the control group (15 % vs. 40 %) and
OS at 1 year improved (27 % vs. 13 %) [13]. However,
75 % of patients had persisting intra-thoracic disease
after chemotherapy, and roughly 90 % had intra-thoracic
disease progression within the first year, so the random-
ized trial of TRT in addition to PCI for ES-SCLC pa-
tients was assessed [15]. All patients who responded to
chemotherapy were targeted for TRT based on the
Fig. 1 Kaplan–Meier Analysis-based Estimates of Survival Based on Prognostic Factors. 1-1. Comparison of survival between patients having small
(≤3 cm) primary tumors (blue) and those having large (>3 cm) primary tumors (red). 1-2. Comparison of survival between patients having single
sites of a distant metastasis (blue) and those having multiple (two or more) sites of distant metastases (red). P-values were determined by the
log-rank test; the number of individuals and the survival times (median (95 % confidence interval), months (mo)) in each group are indicated
Table 3 Multivariate cox proportional hazard model analyses
of prognostic factors for ES-SCLC patients treated with
chemotherapy
Factors HR 95 % CI p
Age ≥75 1.26 0.74–2.14 0.40
Female 2.38 1.11–5.12 0.027
PS 2–4 1.53 0.83–2.81 0.17
Tumor size >3 cm 2.44 1.05–5.68 0.038
Number of metastases ≥2 1.81 1.08–3.04 0.026
LDH high 1.88 0.96–3.67 0.064
Na low 2.50 1.31–4.78 0.006
Note: ES-SCLC extensive-stage small cell lung cancer, HR hazard ratio, CI confi-
dential interval,P S performance status
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results of 1-year OS (33 % vs. 28 %, p = 0.066), 2-year OS
(13 % vs. 3 %, p = 0.004), PFS (4 vs. 3 mo, p = 0.001), the
rates of intra-thoracic progression (19.8 % vs. 46.0 %, p <
0.0001), and no severe toxic effects between the TRT
group and the control group. Although a small number of
the ES-SCLC patients (n = 5) received TRT during the
course of their treatment and the data included limitations
such as selection bias in this study, the survival of the
patients that received local TRT was longer compared
with the other patients (MST: 21.5 mo vs. 9.1 mo,
Additional file 3: Figure S1). Local radiotherapy, includ-
ing TRT, was a standard treatment for patients with
LS-SCLC [3], and was an option for those with ES-
SCLC selected.
Based on previous evidence, adding TRT to chemother-
apy may be a beneficial treatment option for ES-SCLC pa-
tients. To use TRT for ES-SCLC patients, the disease
should be controlled using systemic chemotherapy and
then thoracic lesions to be exposed to radiation should be
identified. B. Jeremic et al. performed a randomized study
for ES-SCLC patients who had a complete response out-
side the thorax and at least a partial response within the
thorax after three cycles of etoposide and cisplatin [17]. D.
Yee et al. conducted a phase II trial of consolidation low
dose TRT for ES-SCLC patients who documented ob-
jective response to at least one cycle of chemotherapy
[18]. B. J Slotman et al. did the phase III randomized
trial for ES-SCLC patients who responded to four to
six cycles of etoposide and platinum chemotherapy
followed by PCI and no clinical evidence of brain,
leptomeningeal, or pleural metastases [15]. We con-
sidered that a targeted population of ES-SCLC should
be selected for the addition of TRT. Our study suggests
that the number of metastatic sites (organs) at diagnosis is
a prognostic factor predicting intra-thoracic progression.
The concept of “oligometastases” defining a small
number of metastases limited to an organ was intro-
duced [19] and revisited [20] for cancer treatments. The
term “oligometastases” describes an intermediate state of
cancer spreading between localized disease and wide-
spread metastases. The patients with limited metastatic
disease, such as liver metastasis from colon cancer, can
be cured by metastasis resection [21]. The concept of
oligo-recurrence is related to the notion that cancer pa-
tients with 1–5 metastatic or recurrent lesions that
could be treated by local therapy have controlled pri-
mary lesions, and oligometastases and oligo-recurrence
may be treated by local therapy such as surgery, radio-
therapy, or radiofrequency ablation [22]. Our study
shows that ES-SCLC patients with oligometastases
should be considered as a population for indication of
TRT to improve their survival.
There is a modest association between the overall
response rate and MST differences in ES-SCLC trials
(R2 = 0.3314), and stronger association in trials wherein
patients with an objective response to the first-line
chemotherapy had undergone subsequent PCI (R2 =
0.6279) [23]. For ES-SCLC, the regimens associated with a
Fig. 2 Disease Progression after First-line Chemotherapy in ES-SCLC Patients without Pleural Effusion (n = 51). Rates (%) of recurrence patterns based
on primary tumor size (≤3 cm vs. >3 cm; 2-1) and the number of metastatic sites (single metastasis vs. multiple metastases; 2-2) at diagnosis are shown.
Blue: thoracic progression, Red: metastases to a distant site, Green: metastases to multiple sites including pleural dissemination and carcinomatous
lymphangiosis, Purple: not evaluable
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lower response rate have a worse outcome [24]. Alterna-
tively, the increased effects of initial treatment may be a
predictive factor of survival for patients with ES-
SCLC, because the majority of SCLC patients relapse
quickly and die of the disease. When we plotted the
PFS and OS differences (Additional file 4: Figure S2),
a modest relationship was detected between them in
the ES-SCLC patients (R2 = 0.49). The increased ef-
fects of initial treatments using combined modalities
might lead to survival benefit in the case of aggressive
disease.
Our study had several limitations. First, this was a
retrospective study from a single institution; the re-
sults cannot be completely regarded as definitive. Sec-
ond, the sample size may not have been sufficient.
The patients had received various types of chemother-
apy, and most patients with ES-SCLC in this study
did not receive clinical TRT. We propose that TRT
should be considered for oligometastatic ES-SCLC.
However, the results of our study should not cause a
treatment change in clinical practice before a more
complete evaluation during clinical trials is done.
A therapeutic plateau has been reached with con-
ventional cytotoxic chemotherapy in ES-SCLC. New
therapeutic approaches for SCLC need to be devel-
oped and predictive biomarkers validated to help
individualize therapy. The favorable prognostic factors
were limited disease spread, good PS, female gender,
young age, the normal level of LDH, response to
therapy and PCI [12, 25]. Around 70 % SCLCs are
metastatic at diagnosis. Tumor volume should be
assessed for combining TRT with systemic chemo-
therapy to evaluate the radiation field. The presence
of circulating tumor cells found in patients with both
LS- and ES-SCLC of peripheral venous blood were
also predictive and prognostic factors [26]. Biomarker
candidates such as tumor marker, circulating tumor
cells, and tumor volumes should be evaluated in the
clinical trials of TRT combined with chemotherapy
for patients with ES-SCLC.
Conclusion
The present study suggested that large tumor size
and multiple distant metastases were poor prognostic
factors in ES-SCLC patients treated with chemother-
apy. Sixty-five percent of ES-SCLC patients with a
single site of distant metastasis had intra-thoracic dis-
ease progression after initial chemotherapy. The use
of TRT may improve the survival in ES-SCLC pa-
tients with limited metastatic disease. TRT should be
considered for ES-SCLC patients with single site of
distant metastasis. The use of TRT in patients with
oligometastatic ES-SCLC should be evaluated in a
clinical trial.
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